Across TCGA pan-cancer cohorts, SPATA21 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SPATA21 data layer compared with 20 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SPATA21 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPATA21 expression acts as an unfavorable survival marker.

PDAC are the cancer types where SPATA21 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.168	0.789	.024	15	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: SPATA21 tumor-vs-normal RNA expression · all SPATA21 data types